APAC MARKETS

我们设法促进高度专业化和具有科学价值的领域的发展,以提高医疗保健的标准。

发现更多关于美纳里尼集团的信息

30 多年来,美纳里尼一直致力于推动研发,为受严重健康问题影响的患者提供创新且有效的药物和医疗保健解决方案。

在13个主要市场获取进入亚太地区所有主要市场的单点式入口。

分享您的合作意向

充分利用我们的全渠道方法使您的品牌在亚太地区增长。

MARKETS

亚太地区的医疗行业正在快速增长。美纳里尼亚太隶属于世界领先的意大利生物制药公司,在该地区13个主要市场拥有强大的布局。

作为众多全球医疗保健公司的首选合作伙伴,我们参与整个药品开发生命周期,挖掘增长机会并扩大其品牌影响力。在此过程中,我们还为医务工作者和患者提供优质医疗产品和技术支持,以提高标准并为未来缔造健康生活。

我们的亚太地区总部

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

新闻

2019 - 09 - 11

MENARINI: ELCIN BARKER ERGUN GROUP CEO

Florence, 12th September 2019 - The Board of Directors has appointed Mrs. Elcin Barker Ergun as CEO of Menarini Group.

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas" commented Eric Cornut, Chairman of Menarini.

Elcin Barker Ergun: "Menarini is a company admired on a global level for both its market dynamism and patient centricity. It is an honour for me to join Menarini and contribute in capturing new business opportunities and further drive our globalization".

"The arrival of Elcin Barker Ergun – commented Lucia and Alberto Giovanni Aleotti – completes the process we started a few years ago with the aim of strengthening the governance and making the company more international in order to accelerate its growth".

After 8 years working in technology sector in the UK and the Netherlands, Elcin Barker Ergun entered the pharmaceutical industry with Smithkline Beecham as subsidiary CFO. She then joined Merck KGaA's Healthcare business where she covered positions of increasing seniority with global business responsibilities as well as managing R&D collaborations in her last role heading New Business.

 

Elcin Barker Ergun has worked in Global, Regional and Local leadership roles in Pharma Industry for more than 20 years including Commercial, Finance and Innovation leadership.
In her last role she was Head of New Business of Merck KGaA's Healthcare division based in Boston in charge of an entity carrying out external development and financing of several assets to create new businesses. Prior to that, she was Executive Vice President, Head of Global Commercial for Merck Serono  responsible for a P&L of €4.5 billion and over 5,000 people. Prior to that, she was Senior Vice President, Head of Intercontinental Region comprising of 69 countries across Middle East, Africa, Turkey, Russia/CIS.
In her earlier career, Elcin held several finance roles as subsidiary CFO Smithkline Beecham and as subsidiary CFO for Honeywell. She also spent 8 years working in technology sector in the UK and the Netherlands, before entering pharma industry. Elcin is an engineer with an MBA from INSEAD.

The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 136 countries worldwide to date, with € 3,667 million in turnover and more than 17,600 employees. With 7 centres for Research & Development, Menarini's products are present in the most important treatment areas, including cardiological, gastroenterological, pneumological, infectious diseases, diabetic and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group's 16 manufacturing plants located in Italy and abroad, which produce and distribute over 585 million packets of product a year. Menarini's pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world.